Filter Results:
(999)
Show Results For
- All HBS Web
(999)
- People (4)
- News (260)
- Research (614)
- Events (9)
- Multimedia (24)
- Faculty Publications (397)
Show Results For
- All HBS Web
(999)
- People (4)
- News (260)
- Research (614)
- Events (9)
- Multimedia (24)
- Faculty Publications (397)
- 08 Aug 2023
- News
The Weight-Loss Drug Frenzy Is Outrunning the Company Behind It
- 08 Jul 2019
- News
What the U.S. can learn from Germany on drug prices
- 2018
- Chapter
The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century
By: Nicholas Bagley, Benjamin Berger, Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
On the 35th anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormous changes in the markets for therapies for rare diseases that have emerged over recent decades. The most prominent example is the fact that the profit-maximizing price of new... View Details
Keywords: Health Care and Treatment; Laws and Statutes; Research and Development; Investment; Markets; Monopoly
Bagley, Nicholas, Benjamin Berger, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern. "The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century." Chap. 4 in Innovation Policy and the Economy, Volume 19, edited by Josh Lerner and Scott Stern, 97–137. University of Chicago Press, 2018.
- 22 Feb 2021
- Working Paper Summaries
Private and Social Returns to R&D: Drug Development and Demographics
- 1994
- Article
The Evolution of Integrative Capability: Innovation in Cardiovascular Drug Discovery
Henderson, Rebecca M. "The Evolution of Integrative Capability: Innovation in Cardiovascular Drug Discovery." Industrial and Corporate Change 3, no. 3 (1994): 607–630.
- August 2020
- Article
A History of Prescription Drug Monitoring Programs in the United States: Political Appeal and Public Health Efficacy
By: A Jay Holmgren, Alyssa Botelho and Allan M Brandt
Prescription drug monitoring programs (PDMPs) have become a widely embraced policy to address the US opioid crisis. Despite mixed scientific evidence on their effectiveness at improving health and reducing overdose deaths, 49 states and Washington, DC have adopted... View Details
Keywords: Health Disorders; Information Technology; Programs; Technology Adoption; History; Government and Politics; Policy; United States
Holmgren, A Jay, Alyssa Botelho, and Allan M Brandt. "A History of Prescription Drug Monitoring Programs in the United States: Political Appeal and Public Health Efficacy." American Journal of Public Health 110, no. 8 (August 2020).
- February 26, 2003
- Article
Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising
By: Joel S. Weissman, David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman and Robert Leitman
Weissman, Joel S., David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman, and Robert Leitman. "Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising." Health Affairs (February 26, 2003).
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
- fall 1994
- Article
Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
Henderson, Rebecca M., and Ian Cockburn. "Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery." Journal of Economics & Management Strategy 3, no. 3 (fall 1994): 481–519.
- 2001
- Working Paper
Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery
By: Stefan Thomke and Walter Kuemmerle
- July 2002
- Article
Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery
By: Stefan Thomke and Walter Kuemmerle
Thomke, Stefan, and Walter Kuemmerle. "Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery." Strategic Management Journal 23, no. 7 (July 2002): 619–635.
- Article
Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
Henderson, Rebecca M., and Iain Cockburn. "Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery." Journal of Industrial Economics 46, no. 2 (June 1998): 157–182.
- January–February 2021
- Article
Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses
By: Rachel E. Weitzman, Ariel Dora Stern and Daniel B. Kramer
As pressure mounts on the Food and Drug Administration (FDA) to speed its review process for novel devices, and budgetary pressures further strain its resources, the critical role of guidance documents in assuring consistent, rigorous, and scientifically grounded... View Details
Keywords: Medical Devices; FDA; Health Care and Treatment; Government Administration; Information; Standards
Weitzman, Rachel E., Ariel Dora Stern, and Daniel B. Kramer. "Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses." American Journal of Therapeutics 28, no. 1 (January–February 2021).
- November 2019
- Case
The Genesis Lab at Novartis
By: Amy C. Edmondson, Ranjay Gulati, Patrick J. Healy and Kerry Herman
Novartis' Genesis Labs program, launched in 2016 as part of Novartis Institutes for Biomedical Research (NIBR), hosted pitch competitions where teams of NIBR scientists proposed ideas to explore that aimed to revolutionize drug discovery. The goal was to break down... View Details
Keywords: Drug Discovery; Health Care and Treatment; Research and Development; Innovation and Invention; Programs; Management
Edmondson, Amy C., Ranjay Gulati, Patrick J. Healy, and Kerry Herman. "The Genesis Lab at Novartis." Harvard Business School Case 620-007, November 2019.
- February 1998 (Revised March 2003)
- Teaching Note
Eli Lilly and Company: Drug Development Strategy (A) and (B) TN
By: Stefan H. Thomke and Ashok Nimgade
Teaching Note for (9-698-010) and (9-698-026). View Details
- spring 1996
- Article
Scale, Scope and Spillovers: The Determinants of Research Productifity in Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
Henderson, Rebecca M., and Ian Cockburn. "Scale, Scope and Spillovers: The Determinants of Research Productifity in Drug Discovery." RAND Journal of Economics 27, no. 1 (spring 1996): 32–59.
- 04 Sep 2014
- News
Our focus was to get drug companies to invest money in ALS
millions of dollars into research, and removed critical barriers to the development of treatments. “Our focus was to get drug companies to invest money in ALS,” says Kremer, who was diagnosed in 2004, just weeks into his first year at... View Details
- June 2021
- Supplement
Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (B)
By: Amitabh Chandra and Spencer Lee-Rey
Chandra, Amitabh, and Spencer Lee-Rey. "Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (B)." Harvard Business School Supplement 621-111, June 2021.